BriaCell opens first Canadian Phase 3 trial site at Sunnybrook’s Odette Cancer Centre in Toronto

BriaCell opened its first Canadian clinical site at Sunnybrook’s Odette Cancer Centre for its pivotal Phase 3 metastatic breast cancer trial.

The Bria-ABC study tests Bria-IMT with an immune checkpoint inhibitor versus physician’s choice; the primary endpoint is overall survival.

The U.S. enrollment footprint exceeds 80 active sites across 15 states; the Canadian launch expands patient access outside the U.S.

An interim analysis is planned once 144 patient deaths occur, comparing mortality between the combination regimen and physician’s choice.